A 10-fold Sensitivity Jump, Broad-band Mass Resolution of >1,000,000 and Sub-ppm Mass Accuracy Make the solariX Ideal for the Analysis of Very Complex Mixtures in
-
Top-Down Proteomics (including ETD & ECD),
-
Petroleomics,
-
Metabolomics, and
-
Small-Molecule Drug and Metabolite MALDI Imaging
BILLERICA, Mass.--(BUSINESS WIRE)--May. 19, 2009--
Bruker Daltonics today launched the solariX™,
its next generation hybrid Qq-FTMS platform. The solariX
is the culmination of a number of key technology developments that
deliver unique capabilities and unparalleled ultra-high resolution mass
spectrometry performance and versatility. At the core of these
innovations are dramatically improved broad-band mass resolving power
(8x over earlier platforms), sensitivity (> 10x over earlier platforms)
and dynamic range. These dramatic improvements help address today’s most
challenging top-down proteomics and complex mixture applications.
Its broad-band, ultra-high resolving power (> 1,000,000 @ m/z 400, for a
7 tesla instrument) and outstanding sub-ppm mass accuracy make the solariX
more powerful than any previous mass spectrometer for the analysis of
extremely complex mixtures. This extraordinary increase in the number of
available m/z channels is essential for tackling very complex mixtures,
especially those that are not amenable to high-resolution chromatography
separation techniques. These applications can include: hydrocarbon
related analysis (“petroleomics”), environmental soil/sediment analysis,
small-molecule biological tissue MALDI imaging, metabolomics, and the
inherently complex peak patterns resulting from top-down proteomics.
For applications that require high performance LC-FTMS or LC-MS/FTMS,
the solariX offers faster and smart data-dependent
acquisition capabilities. Moreover, sub-ppm mass accuracy is maintained
throughout the LC-MS analysis using Bruker’s proprietary Ion Charge
Control (ICC™) method.
Adding to the existing arsenal of top-down proteomics structural
fragmentation tools (ECD, Q-CID, in-cell SORI-CID), solariX
is now the first FTMS system with Electron Transfer Dissociation (ETD).
This exciting new technique is superb for in-depth, comprehensive
analysis of proteins and peptides and their labile, post-translational
modifications (PTMs). ETD-analysis has been fully automated and can be
combined with LC-MS/FTMS workflows in combination with quadrupole
fragmentation (Q-CID) to provide unprecedented levels of protein
structural information. The solariX can also be easily
incorporated into the workflows of other mainstream proteomics platforms
such as the new Bruker ultrafleXtreme MALDI-TOF/TOF (for
high throughput biomarker discovery/quantitation and Edmass™ protein
sequencing) and amaZon ion trap (for high-throughput
LC-MS/MS). The solariX provides complementary analytical
capabilities through the combination of unique dissociation tools with
the performance necessary to address the most challenging structural or
functional proteomics applications, including protein structural studies
and PTM characterization.
The new dual ion funnel source combined with a unique rf ion transfer
system makes the solariX FTMS as intuitive and easy to use
as a benchtop ion trap mass spectrometer. Operation of the instrument is
performed using Bruker’s unified Compass™ software,
enabling researchers to harness the analytical power and versatility of
FTMS with ease.
The solariX can be configured with a unique dual ESI/MALDI
source, and a range of API source options (APCI, GC-APCI, APPI). Low
maintenance, refrigerated magnets are standard at several magnetic field
options, including 7T, 9.4T, 12T and 15T. The solariX is
the realization of the highest performance FTMS product ever released to
the marketplace, equally well suited for small molecule or protein
applications.
Professor André Deelder (Leiden
University Medical Center, Netherlands) commented: “Part of our
mission is to leverage new, enabling technologies for life science
research. Therefore, we are very excited to have received the first two solariX
systems, which are 12 tesla and 15 tesla instruments. The advanced
performance and added capabilities of solariX have been
integrated into our proteomics and metabolomics workflows. They will
increase our capacity for in-depth characterization and quantitative
analysis of the large number of samples generally encountered in
clinical studies, and will enable us to identify more proteins with very
high quantitative precision.”
Professor
Michael Gross
(Washington
University, St. Louis, MO) stated: “Our work in top-down protein
characterization will greatly benefit from the enhanced sensitivity and
ETD capabilities of the solariX FTMS. We have purchased
the solariX 12T system and are very much looking forward
to having it in our laboratory.”
The solariX will be highlighted at Bruker's Annual Users
Meeting on Sunday, May 31st, 2009 before the 57th
ASMS Conference on Mass Spectrometry in Philadelphia, PA. For more
information on this event, please visit www.bdal.com/asms2009
. For further product information, please visit www.bdal.com/solariX
.
ABOUT BRUKER DALTONICS: For more information about Bruker
Daltonics and Bruker Corporation (NASDAQ: BRKR), please visit www.bdal.com
and www.bruker.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5968412&lang=en
Source: Bruker Daltonics
Bruker Daltonics
Darwin Asa, Ph.D., +1 978-663-3660, ext. 1149
Life-Science
Marketing Manager
dja@bdal.com